First Trust Advisors LP Lowers Stake in China Biologic Products Holdings Inc (NASDAQ:CBPO)

Share on StockTwits

First Trust Advisors LP reduced its holdings in shares of China Biologic Products Holdings Inc (NASDAQ:CBPO) by 8.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,999 shares of the biopharmaceutical company’s stock after selling 649 shares during the period. First Trust Advisors LP’s holdings in China Biologic Products were worth $801,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. California Public Employees Retirement System lifted its position in China Biologic Products by 64.2% during the 3rd quarter. California Public Employees Retirement System now owns 51,288 shares of the biopharmaceutical company’s stock valued at $5,871,000 after acquiring an additional 20,047 shares during the period. Nikko Asset Management Americas Inc. raised its holdings in China Biologic Products by 18.1% in the third quarter. Nikko Asset Management Americas Inc. now owns 129,445 shares of the biopharmaceutical company’s stock worth $14,818,000 after buying an additional 19,846 shares during the last quarter. Robeco Institutional Asset Management B.V. purchased a new position in China Biologic Products in the third quarter worth about $2,461,000. York Capital Management Global Advisors LLC raised its holdings in China Biologic Products by 13.9% in the second quarter. York Capital Management Global Advisors LLC now owns 1,128,717 shares of the biopharmaceutical company’s stock worth $107,567,000 after buying an additional 137,484 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in China Biologic Products in the second quarter worth about $486,000. 38.66% of the stock is owned by institutional investors.

Several research analysts have issued reports on the stock. Zacks Investment Research cut shares of China Biologic Products from a “buy” rating to a “hold” rating in a report on Thursday, October 24th. ValuEngine raised shares of China Biologic Products from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. Finally, BidaskClub cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. China Biologic Products presently has a consensus rating of “Hold” and a consensus price target of $92.67.

Shares of China Biologic Products stock opened at $116.63 on Tuesday. The stock has a market capitalization of $4.59 billion, a PE ratio of 29.01, a price-to-earnings-growth ratio of 7.09 and a beta of 1.15. China Biologic Products Holdings Inc has a 52-week low of $70.30 and a 52-week high of $119.44. The company has a 50-day simple moving average of $115.72 and a two-hundred day simple moving average of $102.75.

China Biologic Products (NASDAQ:CBPO) last issued its earnings results on Wednesday, November 13th. The biopharmaceutical company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.52. The business had revenue of $136.10 million during the quarter. China Biologic Products had a net margin of 31.22% and a return on equity of 9.79%. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the firm posted $0.96 earnings per share. On average, research analysts forecast that China Biologic Products Holdings Inc will post 3.29 earnings per share for the current fiscal year.

China Biologic Products Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products Holdings Inc (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.